Dr. Giles has been President, CEO and Director of Vapogenix since July 2017. She joined Vapogenix in 2009 as Chief Scientific Officer and has provided scientific and drug development leadership, in addition to making significant contributions to overall company strategy and to successful fundraising. Dr. Giles has held international leadership positions in large and small pharmaceutical companies and has wide experience in drug discovery and development from target validation, through clinical studies to final regulatory submission. She recently led Vapogenix through the successful completion of a Phase II clinical trial in Australia.
